A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Conditions

• Non-Small Cell Lung Cancer
• Squamous Non-Small Cell Lung Cancer
• NSCLC
• Small Cell Lung Cancer
• SCLC
• Lung Cancer
• Advanced Lung Cancer
• Metastatic Lung Cancer
• Stage IV Lung Cancer

Interventions

• DRUG: Lucitanib

Sponsor

Clovis Oncology, Inc.